RESEARCH ARTICLE

Visceral Fat Accumulation, Insulin Resistance, and Elevated Depressive Symptoms in Middle-Aged Japanese Men

Shuichiro Yamamoto¹ *, Yumi Matsushita², Toru Nakagawa¹, Toru Honda¹, Takeshi Hayashi¹, Mitsuhiko Noda³, Tetsuya Mizoue⁴

¹ Occupational Health Section, Hitachi, Ltd., Hitachi Health Care Center, Hitachi city, Ibaraki, Japan, ² Department of Clinical Research, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan, ³ Department of Endocrinology and Diabetes, Saitama Medical University, Iruma-gun, Saitama, Japan, ⁴ Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan

* shuichiro.yamamoto.sr@hitachi.com

Abstract

Objective

To investigate visceral fat accumulation and markers of insulin resistance in relation to elevated depressive symptoms (EDS).

Methods

Participants were 4,333 male employees (mean age, 49.3 years) who underwent abdominal computed tomography scanning, measured fasting insulin, and did not self-report diabetes and mental disorders under treatment and history of cancer, myocardial infarction, and stroke. Multivariable logistic regression was used to assess the association of EDS with abdominal fat deposition and markers of insulin resistance.

Results

Visceral fat area (VFA) and fasting insulin were significantly, positively associated with EDS. Multivariable-adjusted odds ratios (95% confidence interval) of high VFA for the lowest through highest quartile of depression score were 1 (reference), 1.18 (0.97 – 1.42), 1.25 (1.02 – 1.54), 1.23 (1.01 – 1.51), respectively, and corresponding figures for high fasting insulin were 1 (reference), 0.98 (0.80 – 1.19), 1.12 (0.91 – 1.38), and 1.29 (1.06 – 1.57), respectively. Subcutaneous fat area was not associated with EDS.

Conclusions

Results suggest that EDS is related to visceral, but not subcutaneous, fat accumulation and insulin resistance in middle-aged Japanese men.
Introduction

Numerous studies have reported the association of obesity or diabetes with depression [1–6]. Depression is associated with an increased risk of diabetic complications and mortality among patients with diabetes [7,8]. The relationship between depression and obesity or diabetes may be bidirectional [5,6]. Potential mechanisms underlying these associations include hypothalamic-pituitary-adrenal axis (HPA-axis) dysregulation with hypercortisolemia [9], inflammation [10], influences of lifestyle behaviors [11,12] and side effect of antidepressants [13].

In spite of accumulating epidemiological and experimental evidence linking depression to obesity, it remains unclear which fat deposition is associated with depression. Some studies reported a significant association between abdominal obesity (waist-hip ratio or waist circumference) and depression [14–16], suggesting a role of abdominal adiposity in mood regulation. In small-scale studies with the use of computed tomography (CT) or magnetic resonance tomography, depressed patients had higher visceral fat mass than non-depressed individuals [17–19]. In a few large-scale population-based studies in Western countries that measured abdominal fat deposition with the use of CT [20–22], depressive symptoms were associated with visceral adipose accumulation; of these, one study additionally assessed subcutaneous fat [20] but found no association with depressive symptoms. Given that Japanese men have a larger visceral adipose tissue than Caucasian men in the same levels of waist circumference [23], it would be of interest to examine the association between abdominal adiposity and mood among the Japanese population. As regards glucose metabolism, it remains unclear whether pre-diabetic status including insulin resistance is associated with depression [24]. To address these issues, we investigated cross-sectionally the association of elevated depressive symptoms (EDS) with abdominal fat deposition measured with CT and markers of insulin resistance among Japanese men.

Methods

Study participants

The Hitachi Health Study is an ongoing study among employees (including retired employees) and their spouses who underwent a comprehensive health checkup at Hitachi Health Care Center (Hitachi, Japan), as described elsewhere [25,26]. Of 17,606 examinees during 2008 fiscal year (between April 2008 and March 2009), 6,996 underwent an abdominal CT. Of these, 4,971 non-retired employees received health examinations in fasting condition (fasted at least 12 h) and had data on all variables used in the present study. We excluded 251 patients with diabetes under treatment, 87 patients with mental disorders under treatment, 73 with history of cancer, 20 with history of myocardial infarction and 20 with history of cerebrovascular disease. We excluded 187 women, leaving 4,333 men for analysis. The objective and procedure of the study were announced by using explanatory leaflet and poster. Written informed consent was obtained from each participant who agreed to provide his/her data for research. The study protocol was approved by the Ethics Committee of the Hitachi Health Care Center and the Ethics Committee of National Center for Global Health and Medicine, Japan.

Assessment of exposure (depressive symptoms)

Physical and psychological symptoms were assessed using a questionnaire that was developed for health checkup. From that questionnaire, 13 questions on sleep disturbance, poor appetite, gloomy feeling, diminished interest, fatigue, daily fluctuation, irritation and indecision (Table 1) were selected to assess depression status, according to an advice of a psychiatrist. These questions are similar to those of widely-used depression scales including the Zung Self-
rating Depression Scale (SDS) or the Center for Epidemiologic Studies Depression Scale (CES-D). Specifically, 7 questions selected ('No1', 'No 3', 'No 5', 'No 9', 'No 10', 'No11' and 'No 12') were similar to those in SDS and 5 ('No 7', 'No 8', 'No 9', 'No11'and 'No12') to those in CES-D. Respondents were asked to choose their answer from among 4 response options ('1 no', '2 sometimes', '3 often' and '4 always') for the questions 'No. 1' to 'No. 12' and among 3 options ('1 no', '2 yes' and '3 severe') for the question 'No. 13'. In order to assign an equal weight to all these questions, the scores of 2 and 3 for the question 'No. 13' were converted to 2.5 and 4, respectively. Depression score was then calculated as the sum of the scores across the questions. Pearson correlation coefficient between the score calculated from the selected questions and SDS score was 0.752 [27].

Assessment of outcomes (abdominal obesity and glucose metabolism)

The visceral fat area (VFA) and subcutaneous fat area (SFA) at the umbilical level was measured using a CT scanner (Radix turbo; Hitachi Medico, Tokyo, Japan) while the examinee was in a supine position and estimated using a PC software (fatPointer; Hitachi Medico, Tokyo, Japan). The imaging conditions were 120 kV and 50 mA, using a 5-mm-thick slice. Glucose was measured using glucose oxidase enzyme electrode method (A&T, Tokyo, Japan). Serum insulin (μU/mL) was determined by an immunoenzymatic method using the AxSYM insulin assay (Abbott Laboratories, Tokyo, Japan). Homeostasis model assessment of insulin resistance (HOMA-IR), an index of insulin resistance, was calculated as fasting glucose (mg/dL) multiplied by fasting insulin (μU/mL) divided by 405. Hemoglobin A1c (Japan Diabetes Society [JDS]) was measured using a high-performance liquid chromatography method (HLC723-G9; Tosoh, Tokyo, Japan) and converted to National Glycohemoglobin Standardization Program equivalent value according to the formula: Hemoglobin A1c (%) = Hemoglobin A1c (JDS) (%) + 0.4% [28]. VFA, SFA, fasting insulin and HOMA-IR were categorized into quartiles and the highest groups were defined as outcomes which were named as follows: 'high VFA', 'high SFA', 'high fasting insulin' and 'high HOMA-IR'. 'Overweight/obesity' (BMI ≥25 kg/m²) and 'high fasting glucose' (fasting plasma glucose ≥110 mg/dl) were also defined as outcomes.

Assessment of other variables

Health-related lifestyles including smoking, alcohol drinking, as well as current and past history of diseases including diabetes, cancer, myocardial infarction, stroke and mental disorder were...
ascertained via a questionnaire. As regards physical activity, walking commuting to and from work (min/day) and up to three leisure-time physical activities (frequency and duration of time/day) were asked. MET value (MET-min/week) was calculated by multiplying weekly duration of time engaged in each activity by the corresponding MET, and summing the values across all activities. Height and weight were measured using an automated scale (BF-220; Tanita, Tokyo, Japan). Body mass index (BMI) was calculated as the weight (kg) divided by the square of the height (m²).

Statistical analyses
Baseline characteristics were compared across quartiles of depression score by using one-way analysis of variance (continuous variables) or chi-squared test (categorical variables). The means of age and depression score across quartiles of obesity/metabolic factors were tested by one-way analysis of variance. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for having overweight/obesity, high VFA, high SFA, high fasting glucose, high fasting insulin and high HOMA-IR for each quartile of depression score, with the lowest quartile as the reference. Variables adjusted for in model 1 were age (years, continuous), smoking (never, past or current), alcohol use (nondrinker, drinker consuming <1, 1–1.9 or ≥2 go of sake-equivalent ethanol per day; 1 go of sake contains 23 g ethanol) and leisure time and commuting physical activity (≥400 or <400 METs-min/week). BMI (kg/m², continuous) was additionally adjusted for in model 2. SFA (cm², continuous) was added to model 1 when estimating OR for high VFA (model 3), whereas VFA (cm², continuous) was added to model 1 when estimating OR for high SFA (model 4). We assessed p for trend with 1 to 4 being assigned to increasing quartile of depression score and treated as continuous. All analyses were performed using SPSS for Windows, Version 16.0 (SPSS Inc., IL, USA).

Results
As shown in Table 2, participants with high depression scores were significantly younger and tended not to engage in physical activity than those with low depression scores. Participants in the highest quartile of depression score showed significantly higher SFA, fasting insulin and HOMA-IR levels than those in the lowest quartile of depression score.

As shown in Table 3, participants in the highest quartile of BMI or SFA were significantly younger than those in the lowest BMI or SFA. In contrast, participants with the high VFA (Q2 to Q4) were significantly older than those with the lowest VFA. In univariate analysis, participants in the highest quartile of SFA had significantly higher depression score than those in the lowest SFA. Participants with high level of fasting insulin (Q2 to Q4) and HOMA-IR (Q2 to Q4) had significantly higher depression score than those with the lowest. Table 4 shows the associations between obesity indices, markers of insulin resistance and the depression score. Depression score was significantly associated with VFA and fasting insulin in men; multivariable-adjusted ORs (95% CI) of high VFA for the lowest through highest quartile of depression score were 1 (reference), 1.18 (0.97–1.42), 1.25 (1.02–1.54), 1.23 (1.01–1.51), respectively (P for trend = 0.03), and the corresponding figures for high fasting insulin were 1 (reference), 0.98 (0.80–1.19), 1.12 (0.91–1.38), and 1.29 (1.06–1.57), respectively (P for trend <0.01). There was a suggestion of a positive association between HOMA-IR and depression score (P for trend = 0.06). In contrast, SFA was not associated with depression score (P for trend >0.2). These associations were virtually unchanged after additional adjustment for BMI. The association between VFA and depression score was somewhat attenuated after additional adjustment for SFA and became statistically not significant. The Pearson correlation coefficient between BMI and VFA was 0.641 (P <0.01), between BMI and SFA was 0.778 (P <0.01), and between VFA and SFA was 0.537 (P <0.01).
Discussion

In the present analysis of male employees without treated diabetes and mental disorder, VFA and fasting insulin, but not SFA, were significantly associated with EDS after multivariable adjustment. This study is among a few large-scale population-based studies that reported depressive symptoms in relation to type of abdominal fat deposition and, to our knowledge, the first such study in Asia.

Smaller scale studies (n < 500) that assessed abdominal fat accumulation using a CT or magnetic resonance tomography reported a significant association between depression and visceral fat deposition in women [17–19]. In a large CT study among a middle-aged population (n = 3,299), Murabito et al found a significantly increased odds of depressive symptoms in women, but not in men, with high visceral fat accumulation [20]. Vogelzangs et al showed that high visceral fat at baseline was associated with a significantly increased risk of depression onset in older men, but not in older women [21]. Remigio-Baker et al reported a significant relationship between EDS and visceral adiposity in men, but not in women [22]. Although sex difference in association has been documented, the present result together with previous data suggest a role of VFA in mood disorder.

In a large study of middle-aged men and women [20], subcutaneous adipose tissue was not significantly associated with EDS in both sexes. Similarly, the present study did not find a
significant association between SFA and EDS in men after adjustment for age, denying a role of subcutaneous fat deposition in the etiology of depression. The result is compatible with a weaker association of SFA than VFA with markers of inflammation and insulin resistance [29,30], which are thought to be potential mechanisms underlying the relationship between depression and obesity.

The association between depression and insulin resistance has been inconsistent, with some studies showing a positive association [31,32] while others reporting no association [33,34]. In the present study, odds of high fasting insulin and high HOMA-IR increased by nearly 30% in the highest group of depression score in participants. The finding among participants agrees with those of a meta-analysis [24], reporting a small but significant overall association between depression and insulin resistance.

Several mechanisms whereby depression induces obesity and impaired glucose metabolism have been suggested. Depression is associated with disruption of HPA-axis, which increases blood concentrations of cortisol, leading to insulin resistance [9]. Cortisol and insulin stimulate lipid uptake by activating lipoprotein lipase, and this process is facilitated by high concentrations of cortisol-activate enzyme 11-β-hydroxysteroid dehydrogenase type 1 and glucocorticoid.

| Table 3. Mean value of age and depression score in each quartile of obesity indices/markers of insulin resistance. |
|--------------------------------------------------|
| **Quartile of obesity indices/markers of insulin resistance** |
| **Q1** | **Q2** | **Q3** | **Q4** |
| Body mass index (kg/m²) | <22.2 | 22.2–23.9 | 24–25.7 | ≥25.8 |
| No. of participants | 1,111 | 1,104 | 1,035 | 1,083 |
| Age (years) | 49.5 ± 8.5 | 49.7 ± 8.0 | 49.9 ± 7.9 | 48.1 ± 8.0** |
| Depression score | 19.6 ± 5.8 | 19.9 ± 5.9 | 19.8 ± 6.0 | 20.2 ± 6.4 |
| Visceral fat area (cm²) | <85 | 85–119 | 120–154 | ≥155 |
| No. of participants | 1,093 | 1,095 | 1,067 | 1,078 |
| Age (years) | 47.7 ± 8.9 | 48.8 ± 8.3* | 49.9 ± 7.5** | 50.8 ± 7.5** |
| Depression score | 20.0 ± 6.2 | 19.9 ± 6.1 | 19.8 ± 6.1 | 19.8 ± 5.8 |
| Subcutaneous fat area (cm²) | <97 | 97–127 | 128–164 | ≥165 |
| No. of participants | 1,086 | 1,084 | 1,081 | 1,082 |
| Age (years) | 50.1 ± 8.4 | 50.1 ± 8.1 | 49.9 ± 7.3 | 47.0 ± 7.7** |
| Depression score | 19.4 ± 5.9 | 19.5 ± 5.7 | 19.9 ± 5.8 | 20.7 ± 6.6** |
| Fasting plasma glucose (mg/dL) | <96 | 96–100 | 101–107 | ≥108 |
| No. of participants | 1,185 | 1,019 | 1,087 | 1,107 |
| Age (years) | 47.6 ± 8.6 | 48.7 ± 8.3** | 49.4 ± 7.7*** | 51.5 ± 7.3** |
| Depression score | 20.2 ± 6.1 | 20.0 ± 6.1 | 19.7 ± 6.0 | 19.6 ± 6.0 |
| Fasting insulin (µU/mL) | <3.7 | 3.7–5.2 | 5.3–7.6 | ≥7.7 |
| No. of participants | 1,134 | 1,069 | 1,069 | 1,061 |
| Age (years) | 51.0 ± 8.1 | 49.6 ± 8.1** | 48.7 ± 8.1*** | 47.7 ± 8.0** |
| Depression score | 19.0 ± 5.4 | 19.8 ± 6.1*** | 20.0 ± 6.3** | 20.6 ± 6.2** |
| HOMA-IR | <0.87 | 0.87–1.29 | 1.30–1.96 | ≥1.97 |
| No. of participants | 1,081 | 1,086 | 1,090 | 1,076 |
| Age (years) | 50.9 ± 8.1 | 49.3 ± 8.2** | 48.5 ± 8.1*** | 48.3 ± 7.8** |
| Depression score | 19.1 ± 5.5 | 19.8 ± 6.0* | 20.2 ± 6.2** | 20.5 ± 6.3** |

HOMA-IR: homeostasis model assessment of insulin resistance, Data are means ± standard deviation unless stated otherwise

*P <0.05 and **P <0.01 (versus Q1).

doi:10.1371/journal.pone.0149436.t003
receptors. Visceral fat contains a higher concentration of glucocorticoid receptors and has greater lipoprotein lipase activity than subcutaneous fat [35,36]. In addition, chronic stress causes glucocorticoid receptor resistance that results in a failure to down-regulate response to inflammation [37], which plays an important role in the development of both insulin resistance [38] and obesity [39]. Pro-inflammatory cytokines (such as tumor necrosis factor-α and interleukin-6) have been reported to be increased in depression [18,40] and have also been

### Table 4. Association of elevated depressive symptoms with obesity indices/markers of insulin resistance.

|                          | Quartile of depression score |   |   |   |   |
|--------------------------|------------------------------|---|---|---|---|
|                          | Q1 (<16)                     | Q2 (16–19) | Q3 (20–23) | Q4 (>24) | P for trend |
| Overweight/Obesity       | 435                          | 371         | 298         | 386       | >0.2 |
| Age-adjusted OR (95%CI)  | 1                            | 0.99 (0.83–1.19) | 0.95 (0.79–1.13) | 0.92 (0.77–1.12) | >0.2 |
| OR† (95%CI)              | 1                            | 0.95 (0.80–1.12) | 0.93 (0.77–1.11) | 1.00 (0.84–1.19) | >0.2 |
| High VFA                 | 308                          | 285         | 227         | 258       | 0.02 |
| Age-adjusted OR (95%CI)  | 1                            | 1.18 (0.98–1.43) | 1.26 (1.03–1.54) | 1.25 (1.02–1.52) | 0.03 |
| OR† (95%CI)              | 1                            | 1.18 (0.97–1.42) | 1.25 (1.02–1.54) | 1.23 (1.01–1.51) | >0.2 |
| OR‡ (95%CI)              | 1                            | 1.34 (1.08–1.67) | 1.39 (1.10–1.76) | 1.26 (1.00–1.60) | 0.04 |
| OR§ (95%CI)              | 1                            | 1.21 (0.99–1.49) | 1.24 (0.99–1.55) | 1.16 (0.93–1.44) | 0.17 |
| High SFA                 | 280                          | 257         | 237         | 308       | 0.18 |
| Age-adjusted OR (95%CI)  | 1                            | 0.98 (0.81–1.20) | 1.10 (0.90–1.35) | 1.12 (0.92–1.36) | 0.02 |
| OR† (95%CI)              | 1                            | 0.97 (0.80–1.19) | 1.09 (0.89–1.34) | 1.10 (0.90–1.34) | >0.2 |
| OR‡ (95%CI)              | 1                            | 1.16 (0.90–1.51) | 1.23 (0.93–1.62) | 1.16 (0.89–1.51) | >0.2 |
| OR§ (95%CI)              | 1                            | 0.91 (0.73–1.14) | 0.96 (0.76–1.21) | 1.01 (0.81–1.26) | >0.2 |
| High fasting glucose     | 271                          | 232         | 153         | 192       | >0.2 |
| Age-adjusted OR (95%CI)  | 1                            | 1.10 (0.90–1.35) | 0.96 (0.76–1.20) | 1.12 (0.90–1.40) | >0.2 |
| OR† (95%CI)              | 1                            | 1.11 (0.91–1.41) | 0.96 (0.76–1.20) | 1.13 (0.91–1.41) | >0.2 |
| OR‡ (95%CI)              | 1                            | 1.15 (0.93–1.41) | 0.96 (0.76–1.21) | 1.12 (0.89–1.40) | >0.2 |
| High fasting insulin     | 275                          | 245         | 227         | 314       | <0.01 |
| Age-adjusted OR (95%CI)  | 1                            | 0.98 (0.80–1.19) | 1.13 (0.92–1.38) | 1.28 (1.06–1.56) | <0.01 |
| OR† (95%CI)              | 1                            | 0.98 (0.80–1.19) | 1.12 (0.91–1.38) | 1.29 (1.06–1.57) | <0.01 |
| OR‡ (95%CI)              | 1                            | 1.06 (0.85–1.32) | 1.16 (0.92–1.47) | 1.33 (1.07–1.67) | <0.01 |
| High HOMA-IR             | 294                          | 263         | 213         | 306       | 0.05 |
| Age-adjusted OR (95%CI)  | 1                            | 1.01 (0.83–1.22) | 1.00 (0.82–1.21) | 1.27 (1.03–1.55) | 0.06 |
| OR† (95%CI)              | 1                            | 1.00 (0.83–1.23) | 0.99 (0.81–1.21) | 1.26 (1.02–1.54) | 0.06 |
| OR‡ (95%CI)              | 1                            | 1.09 (0.88–1.35) | 0.99 (0.79–1.23) | 1.28 (1.02–1.62) | 0.11 |

VFA: visceral fat area, SFA: subcutaneous fat area, HOMA-IR: homeostasis model assessment of insulin resistance
OR†: (model 1) Adjusted for age, smoking, alcohol drinking, and physical activity
OR‡: (model 2) Adjusted for age, smoking, alcohol drinking, physical activity and body mass index
OR§: (model 3) Adjusted for age, smoking, alcohol drinking, physical activity and subcutaneous fat area
OR§: (model 4) Adjusted for age, smoking, alcohol drinking, physical activity and visceral fat area

Definition (cutoff) of ‘High’ group (outcome): overweight/obesity ≥25 kg/m², fasting plasma glucose ≥110 mg/dL
highest one-fourth for VFA (≥155 cm²), SFA (≥165 cm²), fasting insulin (≥7.7 μU/mL) and HOMA-IR (≥1.97).

doi:10.1371/journal.pone.0149436.t004
implicated in the development of insulin resistance [38]. Depression could deteriorate lifestyle behaviors including physical activity, dietary habit and sleep rhythm [12]. Similar mechanisms in the opposite direction have also been suggested. Obesity may induce inflammation [41] and HPA-axis dysregulation [42]. Obesity increases risk of insulin resistance and diabetes, which induces cerebral microvascular damage and increase the risk of depression [43,44].

The present study has some limitations. First, the depression score was not assessed based on a validated questionnaire. However, questions used in the calculation of the present depression score were similar to those of standard questionnaires and the present score is well correlated with SDS score. Second, this study is cross-sectional and thus cannot provide data for causal inference. Third, we did not adjust for potentially important variables including diet, which may confound the association. Finally, the study participants were employees of a large-scale company. Caution should be exercised in the application of the present results to a population with a different background.

**Conclusion**

EDS was associated with VFA and markers of insulin resistance in middle-aged Japanese men. Longitudinal studies are required to confirm the present cross-sectional finding and to establish temporality of these relationships.

**Acknowledgments**

The authors thank the participants as well as the clinical and imaging staff at all of the investigator sites.

**Author Contributions**

Conceived and designed the experiments: SY TM. Analyzed the data: SY TN. Contributed reagents/materials/analysis tools: YM T. Hayashi. Wrote the paper: SY TM. Reviewed and edited the manuscript: YM MN T. Honda T. Hayashi.

**References**

1. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934–942. PMID: 10895843
2. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069–1078. PMID: 11375373
3. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23: 1556–1562. PMID: 11023152
4. Kivimäki M, Lawlor DA, Singh-Manoux A, Batty GD, Shipley MJ, et al. Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study. BMJ 2009; 339: b3765. doi: 10.1136/bmj.b3765 PMID: 19808765
5. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220–229. doi: 10.1001/archgenpsychiatry.2010.2 PMID: 20194822
6. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2006; 299: 2751–2759. doi: 10.1001/jama.299.23.2751 PMID: 16860002
7. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001; 63: 619–630. PMID: 11485116
8. Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28: 2668–2672. PMID: 16249537
9. Yokoyama K, Yamada T, Mitani H, Yamada S, Pu S, Yamanashi T, et al. Relationship between hypothalamic-pituitary-adrenal axis dysregulation and insulin resistance in elderly patients with depression. Psychiatry Res 2015; 226: 494–498. doi: 10.1016/j.psychres.2015.01.026 PMID: 25757913

10. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 1279–1283. PMID: 12480034

11. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–2107. PMID: 10904452

12. Lovell GP, Nash K, Sharman R, Lane BR. A cross-sectional investigation of depressive, anxiety, and stress symptoms and health-behavior participation in Australian university students. Nurs Health Sci 2015; 17: 134–142.

13. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002; 14: 175–182. PMID: 12585567

14. Herva A, Laitinen J, Miettunen J, Veijola J, Karvonen JT, Läksy K, et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes 2006; 30: 520–527.

15. Zhao G, Ford ES, Li C, Tsai J, Dhingra S, Balluz LS. Waist circumference, abdominal obesity, and depression among overweight and obese U.S. adults: National Health and Nutrition Examination Survey 2005–2006. BMC Psychiatry 2011; 11: 130. doi: 10.1186/1471-244X-11-130 PMID: 21834955

16. Rivenes AC, Harvey SB, Mykletun A. The relationship between abdominal fat, obesity, and common mental disorders: results from the HUNT study. J Psychosom Res 2009; 66: 269–275. doi: 10.1016/j.jpsychores.2008.07.012 PMID: 19302883

17. Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 1997; 41: 1140–1142. PMID: 9146826

18. Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, Okamura T, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 2006; 30: 1163–1165

19. Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 2013; 36: 480–489. doi: 10.2337/dc12-1442 PMID: 23349152

20. Matsushita Y, Nakagawa T, Yamamoto S, Takahashi Y, Yokoyama T, Noda M, et al. Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals: the Hitachi Health Study. Diabetes Care 2010; 33: 2117–2119. doi: 10.2337/dc10–0120 PMID: 20460443

21. Yokoyama K, Yamada T, Mitani H, Yamada S, Pu S, Yamanashi T, et al. Relationship between hypothalamic-pituitary-adrenal axis dysregulation and insulin resistance in elderly patients with depression. Psychiatry Res 2015; 226: 494–498. doi: 10.1016/j.psychres.2015.01.026 PMID: 25757913

22. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 1279–1283. PMID: 12480034

23. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–2107. PMID: 10904452

24. Herva A, Laitinen J, Miettunen J, Veijola J, Karvonen JT, Läksy K, et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes 2006; 30: 520–527.

25. Zhao G, Ford ES, Li C, Tsai J, Dhingra S, Balluz LS. Waist circumference, abdominal obesity, and depression among overweight and obese U.S. adults: National Health and Nutrition Examination Survey 2005–2006. BMC Psychiatry 2011; 11: 130. doi: 10.1186/1471-244X-11-130 PMID: 21834955

26. Rivenes AC, Harvey SB, Mykletun A. The relationship between abdominal fat, obesity, and common mental disorders: results from the HUNT study. J Psychosom Res 2009; 66: 269–275. doi: 10.1016/j.jpsychores.2008.07.012 PMID: 19302883

27. Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 1997; 41: 1140–1142. PMID: 9146826

28. Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, Okamura T, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 2006; 30: 1163–1165

29. Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 2013; 36: 480–489. doi: 10.2337/dc12-1442 PMID: 23349152

30. Matsushita Y, Nakagawa T, Yamamoto S, Takahashi Y, Yokoyama T, Noda M, et al. Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals: the Hitachi Health Study. Diabetes Care 2010; 33: 2117–2119. doi: 10.2337/dc10–0120 PMID: 20460443

31. Yamamoto S, Matsushita Y, Nakagawa T, Hayashi T, Noda M, Mizoue T. Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. Nutr Diabetes 2014; 4: e130. doi: 10.1038/nrd.2014.27 PMID: 25133442

32. Yakura N. Verification of the Validity of Depressive Symptom Scale. Based on the Existing Health Questionnaire. Asian Pac J Dis Manage 2009; 3: 21–26.
28. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1: 212–228. doi: 10.1111/j.2040-1124.2010.00074.x PMID: 24843435

29. Hsieh CJ, Wang PW, Chen TY. The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults. Diabetol Metab Syndr 2014; 6: 49. doi: 10.1186/1758-5996-6-49 PMID: 24684833

30. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irbeck T, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) 2010; 18: 2191–2198.

31. Pearson S, Schmidt M, Patton G, Dwyer T, Blizzard L, Otahal P, et al. Depression and insulin resistance: cross-sectional associations in young adults. Diabetes Care 2010; 33: 1128–1133. doi: 10.2337/dc09-1940 PMID: 20185745

32. Pyykkönen AJ, Räikkönen K, Tuomi T, Eriksson JG, Groop L, Isomaa B. Depressive symptoms, antidepressant medication use, and insulin resistance: the PPP-Botnia Study. Diabetes Care 2011; 34: 2545–2547. doi: 10.2337/dc11-0107 PMID: 21953801

33. Lawlor DA, Ben-Shlomo Y, Ebrahim S, Davey Smith G, Stansfeld S, Yarnell JW, et al. Insulin resistance and depressive symptoms in middle aged men: findings from the Caerphilly prospective cohort study. BMJ 2005; 330: 705–706. PMID: 15684022

34. Roos C, Lidfeldt J, Agardh CD, Nyberg P, Nerbrand C, Samsioe G, et al. Insulin resistance and self-rated symptoms of depression in Swedish women with risk factors for diabetes: the Women's Health in the Lund Area study. Metabolism 2007; 56: 825–829. PMID: 17512316

35. Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson JA, Björntorp P. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab 1990; 71: 1215–1219. PMID: 2229280

36. Pedersen SB, Jønler M, Richelsen B. Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994; 78: 1354–1359. PMID: 8200937

37. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA 2012; 109: 5995–5999. doi: 10.1073/pnas.1118355109 PMID: 22474371

38. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793–1801. PMID: 16823477

39. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003; 52: 2097–2101. PMID: 12882928

40. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457. doi: 10.1016/j.biopsych.2009.09.033 PMID: 20015486

41. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169–2180. PMID: 17498510

42. Walker BR. Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence? Growth Horm IGF Res 2001; 11 Suppl A: S91–95. PMID: 11527096

43. Huber JD. Diabetes, cognitive function, and blood-brain barrier. Curr Pharm Des 2008; 14: 1594–1600. PMID: 18673200

44. Ajilore O, Haroon E, Kumaran S, Darwin C, Binesh N, Mintz J, et al. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology 2007; 32: 1224–1231. PMID: 17180124